Salubris(002294)2024-10-21 10:42Financial Performance - The company's revenue for Q3 2024 reached ¥958.43 million, representing a 24.15% increase compared to ¥772.02 million in the same period last year[3]. - Net profit attributable to shareholders was ¥165.62 million, up 17.01% from ¥141.55 million year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥163.60 million, a 30.87% increase from ¥122.50 million in the previous year[4]. - The company achieved a net cash flow from operating activities of ¥853.91 million, a significant increase of 59.63% compared to ¥534.95 million last year[4]. - Basic earnings per share rose to ¥0.1500, reflecting a 15.38% increase from ¥0.1300 in the same period last year[4]. - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[26]. - The net profit for Q3 2024 was CNY 512,089,093.42, an increase of 7.3% compared to CNY 477,193,190.66 in Q3 2023[27]. - The total profit for Q3 2024 was CNY 574,289,522.43, an increase from CNY 549,960,968.69 in Q3 2023, marking a growth of 4.4%[27]. Revenue Growth - The company reported a 22.18% year-on-year increase in revenue for the first three quarters of 2024, totaling ¥3.00 billion[8]. - Total operating revenue for Q3 2024 reached CNY 3,001,062,877.67, an increase of 22.2% compared to CNY 2,456,303,071.76 in Q3 2023[26]. - The total revenue from operating activities reached CNY 3,215,244,492.35, up from CNY 2,679,650,386.06 in the same period last year, representing a growth of 20%[29]. Investment and R&D - The company is actively promoting and expanding the market for its innovative product Ennarro, which has shown good progress in hospital access and clinical application[8]. - Research and development projects are progressing smoothly, with several Phase III clinical trials underway for new drugs[9]. - The company has increased its investment in product promotion and innovation, contributing to revenue and profit growth[8]. - R&D expenses increased to CNY 306,484,951.33, representing a rise of 19.6% compared to CNY 256,275,653.77 in Q3 2023[26]. - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[26]. Cash Flow and Assets - The total assets at the end of the reporting period were ¥10.23 billion, an 8.90% increase from ¥9.40 billion at the end of the previous year[4]. - The cash flow from operating activities generated a net amount of CNY 853,910,406.63, compared to CNY 534,945,874.41 in Q3 2023, indicating a significant increase of 59.7%[29]. - Cash received from investment recoveries increased by CNY 424.3586 million, a growth of 56.95%, mainly due to increased recoveries from financial product investments[10]. - The total current assets as of September 30, 2024, amounted to ¥3,760,737,600.91, an increase from ¥3,313,221,923.67 at the beginning of the period[23]. - Cash and cash equivalents decreased to ¥1,027,509,567.02 from ¥1,321,975,062.75[23]. Financial Management - The company raised a total of RMB 195,187.12 million by issuing 68,800,535 shares at RMB 28.37 per share, with a net amount of RMB 193,206.57 million after deducting issuance costs[16]. - The balance of the raised funds account as of September 30, 2024, is RMB 95,413.32 million, with interest income of RMB 585.06 million accrued during the year[16]. - The company has entrusted RMB 157,978.00 million in financial management products, with a remaining balance of RMB 133,619.01 million[18]. - The company has no overdue amounts in its entrusted financial management, and all amounts have been fully recovered[19]. - The expected annualized return rates for various financial products range from 1.0% to 3.7%[20]. Liabilities and Equity - Total liabilities increased to CNY 1,587,942,524.39, a rise of 18.4% from CNY 1,341,246,394.27 in the previous year[25]. - The company's equity attributable to shareholders was CNY 8,606,631,778.95, up 7.3% from CNY 8,018,993,837.21 in Q3 2023[25]. Other Financial Metrics - Deferred revenue increased by CNY 37.107 million, a growth of 44.12%, mainly due to an increase in government subsidy receipts[10]. - Sales expenses increased by CNY 383.989 million, a growth of 53.65%, primarily due to increased promotional expenses for newly launched products and enhanced promotion of existing products[10]. - Financial expenses increased by CNY 25.2801 million, a growth of 52.47%, mainly due to reduced deposits and lower interest income[10]. - The company experienced a foreign exchange loss of CNY 6,071,046.19 in Q3 2024, compared to a gain of CNY 15,397,241.22 in Q3 2023[27]. - The company reported a decrease in credit impairment losses to CNY -7,052,363.56 from CNY -11,059,771.61 in the previous year, indicating improved asset quality[27].